A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias

SIMPLE SUMMARY: Target-oriented drugs are profoundly changing the anti-cancer treatments. Progression-free survival is a primary or co-primary endpoint in the large part of comparative and translational clinical trials about target-oriented anti-cancer agents. In this context, the time before treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Santorsola, Mariachiara, Caraglia, Michele, Nasti, Guglielmo, Ottaiano, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654809/
https://www.ncbi.nlm.nih.gov/pubmed/36358684
http://dx.doi.org/10.3390/cancers14215265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654809/
https://www.ncbi.nlm.nih.gov/pubmed/36358684
http://dx.doi.org/10.3390/cancers14215265

Ejemplares similares